New drug probe aims to measure niraparib's brain tumor penetration
NCT ID NCT05406700
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-stage trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for one month before their operation so researchers can measure how much drug reaches the tumor and how it affects cancer cells. The goal is to gather information, not to treat the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a parasite drug fight childhood brain tumors?
- A new PET scan tracks brain tumors by their appetite for tryptophan
- Can a simple dye help surgeons see brain tumors in real time?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Digital tests may offer a new way to track brain health in tumor patients
- Targeted antibody may boost brain cancer treatment after incomplete surgery